FDA Approves Calaspargase Pegol-mknl for Pediatric and Young Adult Patients With ALL

December 20, 2018 – On December 20, 2018, the U.S. Food and Drug Administration (FDA) approved calaspargase pegol-mknl (Asparlas), an asparagine-specific enzyme, as a component of a multiagent chemotherapeutic regimen for acute lymphoblastic leukemia (ALL) in pediatric and young adult patients aged 1 month to 21 years. This new product provides for a longer interval between doses compared to other available pegaspargase products. Approval was … (leggi tutto)